Mechanism-based combination telomerase inhibition therapy

Jerry W. Shay, Woodring E. Wright

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Inhibition of telomerase is an exciting therapeutic target, since it is required for the long-term proliferation of most cancer cells but not present in most somatic cells. However, effective telomerase inhibitors have yet to be tested in clinical trials. In this issue of Cancer Cell, Seimiya and coworkers (Seimiya et al., 2005) explore inhibiting tankyrase, an enzyme involved in making telomeres accessible to telomerase. Adding a partial inhibition of tankyrase to a partial inhibition of telomerase drove cancer cells into crisis and death. The combination of tankyrase and telomerase inhibitors may offer new opportunities for realizing the promise of telomerase inhibition therapy.

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalCancer Cell
Volume7
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Telomerase
Tankyrases
Therapeutics
Neoplasms
Telomere
Clinical Trials
Enzymes

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Mechanism-based combination telomerase inhibition therapy. / Shay, Jerry W.; Wright, Woodring E.

In: Cancer Cell, Vol. 7, No. 1, 01.2005, p. 1-2.

Research output: Contribution to journalArticle

Shay, Jerry W. ; Wright, Woodring E. / Mechanism-based combination telomerase inhibition therapy. In: Cancer Cell. 2005 ; Vol. 7, No. 1. pp. 1-2.
@article{59a2919535dd429d9430f5886376fedc,
title = "Mechanism-based combination telomerase inhibition therapy",
abstract = "Inhibition of telomerase is an exciting therapeutic target, since it is required for the long-term proliferation of most cancer cells but not present in most somatic cells. However, effective telomerase inhibitors have yet to be tested in clinical trials. In this issue of Cancer Cell, Seimiya and coworkers (Seimiya et al., 2005) explore inhibiting tankyrase, an enzyme involved in making telomeres accessible to telomerase. Adding a partial inhibition of tankyrase to a partial inhibition of telomerase drove cancer cells into crisis and death. The combination of tankyrase and telomerase inhibitors may offer new opportunities for realizing the promise of telomerase inhibition therapy.",
author = "Shay, {Jerry W.} and Wright, {Woodring E.}",
year = "2005",
month = "1",
doi = "10.1016/j.ccr.2004.12.012",
language = "English (US)",
volume = "7",
pages = "1--2",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Mechanism-based combination telomerase inhibition therapy

AU - Shay, Jerry W.

AU - Wright, Woodring E.

PY - 2005/1

Y1 - 2005/1

N2 - Inhibition of telomerase is an exciting therapeutic target, since it is required for the long-term proliferation of most cancer cells but not present in most somatic cells. However, effective telomerase inhibitors have yet to be tested in clinical trials. In this issue of Cancer Cell, Seimiya and coworkers (Seimiya et al., 2005) explore inhibiting tankyrase, an enzyme involved in making telomeres accessible to telomerase. Adding a partial inhibition of tankyrase to a partial inhibition of telomerase drove cancer cells into crisis and death. The combination of tankyrase and telomerase inhibitors may offer new opportunities for realizing the promise of telomerase inhibition therapy.

AB - Inhibition of telomerase is an exciting therapeutic target, since it is required for the long-term proliferation of most cancer cells but not present in most somatic cells. However, effective telomerase inhibitors have yet to be tested in clinical trials. In this issue of Cancer Cell, Seimiya and coworkers (Seimiya et al., 2005) explore inhibiting tankyrase, an enzyme involved in making telomeres accessible to telomerase. Adding a partial inhibition of tankyrase to a partial inhibition of telomerase drove cancer cells into crisis and death. The combination of tankyrase and telomerase inhibitors may offer new opportunities for realizing the promise of telomerase inhibition therapy.

UR - http://www.scopus.com/inward/record.url?scp=12344288452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344288452&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2004.12.012

DO - 10.1016/j.ccr.2004.12.012

M3 - Article

C2 - 15652743

AN - SCOPUS:12344288452

VL - 7

SP - 1

EP - 2

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 1

ER -